QQQ   308.28 (+2.45%)
AAPL   149.32 (+2.67%)
MSFT   259.42 (+2.64%)
META   182.47 (+19.17%)
GOOGL   106.67 (+6.21%)
AMZN   110.30 (+4.90%)
TSLA   189.64 (+4.54%)
NVDA   213.86 (+2.12%)
NIO   12.10 (+0.00%)
BABA   110.01 (-2.49%)
AMD   85.76 (+1.32%)
T   20.10 (-0.40%)
MU   63.10 (+0.80%)
F   14.20 (+2.97%)
CGC   3.15 (+2.27%)
GE   82.42 (+0.12%)
DIS   110.25 (+0.79%)
AMC   6.16 (+7.88%)
PFE   43.83 (-0.32%)
PYPL   86.61 (+4.46%)
NFLX   361.64 (-0.10%)
QQQ   308.28 (+2.45%)
AAPL   149.32 (+2.67%)
MSFT   259.42 (+2.64%)
META   182.47 (+19.17%)
GOOGL   106.67 (+6.21%)
AMZN   110.30 (+4.90%)
TSLA   189.64 (+4.54%)
NVDA   213.86 (+2.12%)
NIO   12.10 (+0.00%)
BABA   110.01 (-2.49%)
AMD   85.76 (+1.32%)
T   20.10 (-0.40%)
MU   63.10 (+0.80%)
F   14.20 (+2.97%)
CGC   3.15 (+2.27%)
GE   82.42 (+0.12%)
DIS   110.25 (+0.79%)
AMC   6.16 (+7.88%)
PFE   43.83 (-0.32%)
PYPL   86.61 (+4.46%)
NFLX   361.64 (-0.10%)
QQQ   308.28 (+2.45%)
AAPL   149.32 (+2.67%)
MSFT   259.42 (+2.64%)
META   182.47 (+19.17%)
GOOGL   106.67 (+6.21%)
AMZN   110.30 (+4.90%)
TSLA   189.64 (+4.54%)
NVDA   213.86 (+2.12%)
NIO   12.10 (+0.00%)
BABA   110.01 (-2.49%)
AMD   85.76 (+1.32%)
T   20.10 (-0.40%)
MU   63.10 (+0.80%)
F   14.20 (+2.97%)
CGC   3.15 (+2.27%)
GE   82.42 (+0.12%)
DIS   110.25 (+0.79%)
AMC   6.16 (+7.88%)
PFE   43.83 (-0.32%)
PYPL   86.61 (+4.46%)
NFLX   361.64 (-0.10%)
QQQ   308.28 (+2.45%)
AAPL   149.32 (+2.67%)
MSFT   259.42 (+2.64%)
META   182.47 (+19.17%)
GOOGL   106.67 (+6.21%)
AMZN   110.30 (+4.90%)
TSLA   189.64 (+4.54%)
NVDA   213.86 (+2.12%)
NIO   12.10 (+0.00%)
BABA   110.01 (-2.49%)
AMD   85.76 (+1.32%)
T   20.10 (-0.40%)
MU   63.10 (+0.80%)
F   14.20 (+2.97%)
CGC   3.15 (+2.27%)
GE   82.42 (+0.12%)
DIS   110.25 (+0.79%)
AMC   6.16 (+7.88%)
PFE   43.83 (-0.32%)
PYPL   86.61 (+4.46%)
NFLX   361.64 (-0.10%)
NASDAQ:GALT

Galectin Therapeutics - GALT Stock Forecast, Price & News

$1.15
-0.01 (-0.86%)
(As of 02/1/2023 12:00 AM ET)
Add
Compare
Today's Range
$1.15
$1.18
50-Day Range
$1.03
$1.35
52-Week Range
$1.02
$2.57
Volume
56,794 shs
Average Volume
61,311 shs
Market Capitalization
$68.55 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$11.00

Galectin Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
856.5% Upside
$11.00 Price Target
Short Interest
Bearish
4.69% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.87mentions of Galectin Therapeutics in the last 14 days
Based on 2 Articles This Week
Insider Trading
Acquiring Shares
$6,723 Bought Last Quarter
Proj. Earnings Growth
Decreasing
From ($0.65) to ($0.83) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.06 out of 5 stars

Medical Sector

541st out of 1,030 stocks

Pharmaceutical Preparations Industry

271st out of 502 stocks


GALT stock logo

About Galectin Therapeutics (NASDAQ:GALT) Stock

Galectin Therapeutics, Inc. is a biotechnology company, which engages in drug research and development to create new therapies for fibrotic disease, severe skin disease, and cancer. Its programs target the development of carbohydrate molecules which offers alternative options to larger market segments. The company was founded by James C. Czirr and Anatole A. Klyosov on July 10, 2000 and is headquartered in Norcross, GA.

Receive GALT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Galectin Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

GALT Stock News Headlines

Know Your Profit Potential BEFORE You Trade!
I’m Chuck Hughes, ten-time trading champion and author of the coveted e-book, “Options Trading Made Easy”, the strategy guide that will teach you to calculate your trade’s profit potential before you risk any capital. Click here for a free copy now! pixel
Galectin Therapeutics: In For A Long 2-Year Wait
Cash Holders STILL Aren't Taking Steps to Prepare
Stocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.
Galectin Therapeutics to Present in Upcoming Conferences
Galectin Therapeutics Inc. (GALT)
Galectin Therapeutics GAAP EPS of -$0.17
See More Headlines
Receive GALT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Galectin Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

GALT Company Calendar

Last Earnings
11/14/2022
Today
2/02/2023
Next Earnings (Estimated)
3/30/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:GALT
Employees
6
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$11.00
High Stock Price Forecast
$11.00
Low Stock Price Forecast
$11.00
Forecasted Upside/Downside
+856.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-30,530,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.01 per share

Miscellaneous

Free Float
32,962,000
Market Cap
$68.55 million
Optionable
Optionable
Beta
1.60

Key Executives

  • Joel Lewis
    President, Chief Executive Officer & Director
  • Jack W. Callicutt
    Chief Financial Officer & Secretary
  • Pol F. Boudes
    Chief Medical Officer
  • Ezra R. lowe
    Executive Director-Clinical
  • Marla Mills-Wilson
    Executive Director-Clinical Operations













GALT Stock - Frequently Asked Questions

Should I buy or sell Galectin Therapeutics stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Galectin Therapeutics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" GALT shares.
View GALT analyst ratings
or view top-rated stocks.

What is Galectin Therapeutics' stock price forecast for 2023?

1 equities research analysts have issued 12 month target prices for Galectin Therapeutics' shares. Their GALT share price forecasts range from $11.00 to $11.00. On average, they anticipate the company's stock price to reach $11.00 in the next year. This suggests a possible upside of 856.5% from the stock's current price.
View analysts price targets for GALT
or view top-rated stocks among Wall Street analysts.

How have GALT shares performed in 2023?

Galectin Therapeutics' stock was trading at $1.13 on January 1st, 2023. Since then, GALT stock has increased by 1.8% and is now trading at $1.15.
View the best growth stocks for 2023 here
.

When is Galectin Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 30th 2023.
View our GALT earnings forecast
.

How were Galectin Therapeutics' earnings last quarter?

Galectin Therapeutics Inc. (NASDAQ:GALT) released its quarterly earnings data on Monday, November, 14th. The company reported ($0.14) EPS for the quarter, topping analysts' consensus estimates of ($0.20) by $0.06.

What other stocks do shareholders of Galectin Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Galectin Therapeutics investors own include Sorrento Therapeutics (SRNE), Catalyst Pharmaceuticals (CPRX), Viking Therapeutics (VKTX), Exelixis (EXEL), Progenics Pharmaceuticals (PGNX), Rigel Pharmaceuticals (RIGL), TherapeuticsMD (TXMD), Novavax (NVAX), Verastem (VSTM) and Immunomedics (IMMU).

What is Galectin Therapeutics' stock symbol?

Galectin Therapeutics trades on the NASDAQ under the ticker symbol "GALT."

Who are Galectin Therapeutics' major shareholders?

Galectin Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Geneos Wealth Management Inc. (0.73%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Elissa J Schwartz, Fund LP 10X, Gilbert F Amelio, Jack W Callicutt, Kary Eldred, Kevin D Freeman and Richard A Jr Zordani.
View institutional ownership trends
.

How do I buy shares of Galectin Therapeutics?

Shares of GALT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Galectin Therapeutics' stock price today?

One share of GALT stock can currently be purchased for approximately $1.15.

How much money does Galectin Therapeutics make?

Galectin Therapeutics (NASDAQ:GALT) has a market capitalization of $68.55 million. The company earns $-30,530,000.00 in net income (profit) each year or ($0.59) on an earnings per share basis.

How can I contact Galectin Therapeutics?

Galectin Therapeutics' mailing address is 4960 PEACHTREE INDUSTRIAL BLVD. SUITE 240, NORCROSS GA, 30071. The official website for the company is www.galectintherapeutics.com. The company can be reached via phone at (678) 620-3186, via email at ir@galectintherapeutics.com, or via fax at 770-864-1327.

This page (NASDAQ:GALT) was last updated on 2/2/2023 by MarketBeat.com Staff